Urinary RNA Biomarker Testing for Prostate Cancer Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing prostate cancer, such as the PSA test, have low sensitivity and specificity, leading to invasive biopsies with complications, and existing urine-based tests are not effective in distinguishing prostate cancer from benign prostate hyperplasia.
Innovation Solution
A method for diagnosing prostate cancer by assessing urinary RNA levels, specifically focusing on the amount of RNA encoding diagnostic genes in the soluble urine fraction, using techniques like ultrafiltration and RT-PCR to generate a diagnostic score compared to a reference value.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PSA test is used to diagnose prostate cancer, then the diagnosis can be performed, but the sensitivity and specificity are low leading to unnecessary biopsies
Solution Approach 1:
The patent introduces an intermediary diagnostic test using urinary RNA biomarkers (PCA3, TMPRSS2:ERG, PSA) that mediates between the initial PSA screening and the invasive biopsy. This intermediary test provides more accurate molecular information about prostate cancer presence, allowing clinicians to avoid unnecessary biopsies while maintaining high diagnostic accuracy for detecting prostate cancer.
Solution Approach 2:
The patent changes the diagnostic parameters from measuring only serum PSA levels to measuring multiple urinary RNA biomarkers including PCA3, TMPRSS2:ERG fusion transcripts, and PSA RNA. This parameter change provides a more comprehensive molecular profile of prostate cancer, significantly improving diagnostic precision and reducing false positives that lead to unnecessary biopsies.
2Measurement precision
If biopsy is performed to confirm prostate cancer diagnosis, then accurate diagnosis can be obtained, but invasive procedures and complications occur
Solution Approach 1:
The patent replaces the mechanical invasive biopsy procedure with a molecular diagnostic system that analyzes urinary RNA biomarkers. This substitution eliminates the need for physical tissue sampling while providing equivalent or superior diagnostic accuracy through detection of cancer-specific molecular signatures including PCA3 overexpression and TMPRSS2:ERG fusion transcripts in urine samples.
Solution Approach 2:
The patent extracts and analyzes specific RNA biomarkers (PCA3, TMPRSS2:ERG, PSA) from urinary samples to obtain diagnostic information. By extracting and measuring these specific molecular markers, the system achieves accurate cancer detection without requiring extraction of tissue through invasive biopsy, thereby avoiding biopsy-related complications.
3Ease of operation
If existing urine-based tests are used, then non-invasive diagnosis is achieved, but they are not effective in distinguishing prostate cancer from benign prostate hyperplasia
Solution Approach 1:
The patent creates a multi-functional urinary RNA diagnostic system that simultaneously detects and distinguishes between prostate cancer and benign prostate hyperplasia using multiple biomarkers (PCA3, TMPRSS2:ERG, PSA). This universal test platform handles both cancer detection and BPH differentiation within a single non-invasive urine analysis, eliminating the need for separate diagnostic procedures.
Solution Approach 2:
The patent applies local quality by focusing on cancer-specific molecular signatures within the urinary RNA profile, particularly PCA3 overexpression and TMPRSS2:ERG fusion transcripts that are specifically associated with prostate cancer rather than BPH. By targeting these specific molecular markers with high local specificity, the test achieves accurate differentiation between cancer and benign conditions while maintaining non-invasive sampling.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach improves the accuracy of prostate cancer diagnosis by providing a non-invasive method with higher sensitivity and specificity, reducing the need for unnecessary biopsies and associated complications.
Implementation Method 1
The RNA in the soluble urine fraction may be concentrated to form a soluble urine concentrate by any suitable means including, for example, ultrafiltration (e.g., using a filter membrane having a cutoff of about 100 kDa, 50 kDa, 10 kDa, or 3 kDa)
Implementation Method 2
determining the amount of RNA encoding one or more diagnostic genes in the soluble urine fraction
Data Source
AI summary
The invention provides methods for isolating RNA from whole urine and urine fractions for the diagnosis of prostate cancer and/or benign prostate hyperplasia. An exemplary method for diagnosing prostate cancer in an individual, said method comprises: (a) determining the amount of RNA encoding one or more diagnostic genes in the soluble urine fraction of a urine sample obtained from said individual; (b) comparing the amount of said RNA to a reference value for said one or more diagnostic genes, wherein said reference value is derived from the amount of RNA encoding said one or more diagnostic genes in one or more individuals that do not have prostate cancer; and (c) diagnosing said individual as having prostate cancer when the amount of said RNA is greater than said reference value.